HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 4 (April)

1. Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.
   J Med Virol, 80(5): 747-53. [Abstract] [Full-text]
2. National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation.
   J Med Virol, 80(5): 762-5. [Abstract] [Full-text]
3. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.
   J Med Virol, 80(5): 754-61. [Abstract] [Full-text]
4. Viral diversity limits immune diversity in asymptomatic phase of HIV infection.
   Theor Popul Biol, 73(3): 332-41. [Abstract] [Full-text]
5. Salivary microbiota of HIV-positive children and its correlation with HIV status, oral diseases, and total secretory IgA.
   Int J Paediatr Dent, 18(3): 205-16. [Abstract] [Full-text]
6. Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals.
   J Clin Microbiol, 46(4): 1494-7. [Abstract] [Full-text]
7. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.
   Biol Psychiatry, 63(9): 899-905. [Abstract] [Full-text]
8. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues.
   J Antimicrob Chemother, 61(5): 973-5. [Abstract] [Full-text]
9. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
   J Antimicrob Chemother, 61(5): 1145-53. [Abstract] [Full-text]
10. HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes.
    Cell Microbiol, 10(5): 1040-57. [Abstract] [Full-text]
11. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
    Biochem Biophys Res Commun, 370(1): 22-6. [Abstract] [Full-text]
12. Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.
    Clin Exp Immunol, 152(2): 252-7. [Abstract] [Full-text]
13. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges.
    Clin Exp Immunol, 152(2): 201-10. [Abstract] [Full-text]
14. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study.
    J Infect Dis, 197(7): 1011-5. [Abstract] [Full-text]
15. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons.
    J Infect Dis, 197(7): 990-9. [Abstract] [Full-text]
16. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Clin Infect Dis, 46(10): 1617-23. [Abstract] [Full-text]
17. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
    Clin Infect Dis, 46(10): 1589-97. [Abstract] [Full-text]
18. Unexpected roles for UPF1 in HIV-1 RNA metabolism and translation.
    RNA, 14(5): 914-27. [Abstract] [Full-text]
19. Selection of peptides interfering with a ribosomal frameshift in the human immunodeficiency virus type 1.
    RNA, 14(5): 981-91. [Abstract] [Full-text]
20. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.
    PLoS ONE, 3(4): e2021. [Abstract] [Full-text]
21. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering.
    PLoS ONE, 3(4): e1999. [Abstract] [Full-text]
22. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings.
    PLoS ONE, 3(4): e1988. [Abstract] [Full-text]
23. Mutations in the human immunodeficiency virus type 1 polypurine tract (PPT) reduce the rate of PPT cleavage and plus-strand DNA synthesis.
    J Virol, 82(10): 5104-8. [Abstract] [Full-text]
24. CD63 is not required for production of infectious human immunodeficiency virus type 1 in human macrophages.
    J Virol, 82(10): 4751-61. [Abstract] [Full-text]
25. Efficient and specific rescue of human immunodeficiency virus type 1 budding defects by a Nedd4-like ubiquitin ligase.
    J Virol, 82(10): 4898-907. [Abstract] [Full-text]
26. NEDD4L overexpression rescues the release and infectivity of human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late domains.
    J Virol, 82(10): 4884-97. [Abstract] [Full-text]
27. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection.
    J Virol, 82(10): 4785-92. [Abstract] [Full-text]
28. GGA and Arf proteins modulate retrovirus assembly and release.
    Mol Cell, 30(2): 227-38. [Abstract] [Full-text]
29. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.
    J Med Virol, 80(6): 953-9. [Abstract] [Full-text]
30. Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious diseases in Northern Italy.
    J Med Virol, 80(6): 947-52. [Abstract] [Full-text]
31. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    J Med Virol, 80(6): 942-6. [Abstract] [Full-text]
32. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.
    J Med Virol, 80(6): 937-41. [Abstract] [Full-text]
33. A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
    J Mol Biol, 378(3): 565-80. [Abstract] [Full-text]
34. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
    J Acquir Immune Defic Syndr, 48(1): 26-34. [Abstract] [Full-text]
35. Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy.
    J Acquir Immune Defic Syndr, 48(1): 68-71. [Abstract] [Full-text]
36. HIV-1 upregulates VEGF in podocytes.
    J Am Soc Nephrol, 19(5): 877-83. [Abstract] [Full-text]
37. HIV-1 Tat inhibits NGF-induced Egr-1 transcriptional activity and consequent p35 expression in neural cells.
    J Cell Physiol, 216(1): 128-34. [Abstract] [Full-text]
38. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells.
    PLoS ONE, 3(4): e2035. [Abstract] [Full-text]
39. Coinfection with HIV-1 and simian foamy virus in West Central Africans.
    J Infect Dis, 197(10): 1389-93. [Abstract] [Full-text]
40. HIV-1 tropism and survival in vertically infected Ugandan infants.
    J Infect Dis, 197(10): 1382-8. [Abstract] [Full-text]
41. Maternal-fetal DNA admixture is associated with intrapartum mother-to-child transmission of HIV-1 in Blantyre, Malawi.
    J Infect Dis, 197(10): 1378-81. [Abstract] [Full-text]
42. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
    J Infect Dis, 197(10): 1361-8. [Abstract] [Full-text]
43. Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection.
    J Infect Dis, 197(10): 1369-77. [Abstract] [Full-text]
44. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
    J Infect Dis, 197(10): 1408-18. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.